Lentechs Announces Successful $6 Million Fundraise to Further Key Development Objectives

COLUMBUS, OH, Oct 17, 2023 – Lentechs, a clinical-stage ophthalmic medical device company developing a new generation of soft, suspended contact lens, designed to transform the treatment paradigm for presbyopia, today announced the closing of a successful fundraise to further key development objectives for its investigational contact lens for patients with presbyopia. The round was led by Vision Vestments LLC, with additional significant investments from JobsOhio Growth Capital Fund, Ohio Innovation Fund, Bluestem Capital, and Rev1 Ventures.

“This milestone signifies the strength and confidence in Lentechs and our APIOC®, a first-of-its-kind line of soft, suspended contact lens designed to deliver exceptional, glasses-like vision at all distances with the freedom of a contact lens. Proceeds will be utilized to finalize industry-leading manufacturing methods and additional randomized clinical trials that will test molded APIOC vs the leading multifocal contact lenses from each of the Big-4 contact lens manufacturers,” stated Mr. Robin G. Sears, CEO of Lentechs. “Thank you to all our Board of Directors members and the investors in our company for their continued support to improve visual outcomes for millions of people worldwide.”

Read the remainder of the press release by clicking here.

Shared by Tyler Stowater, board member of Lentechs.